Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX07 plus Serplulimab and Chemotherapy in NPC
NCT05513573Phase 2Active, not recruiting
- Sponsor
- Henlius
- Start
- Dec 2022
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pimurutamab in nasopharyngeal carcinoma (NPC), sponsored by Henlius. Started Dec 2022; status: active, not recruiting.
02
Drugs
pimurutamab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05513573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05513573.